About International AIDS Vaccine Initiative (IAVI)
A nonprofit organization, founded in 1996, making vaccines & antibodies for AIDS/TBC and infectious diseases accessible and affordable. -> Full circle approach: discovery, epidemiology & research, clinical development, policy, access, advocacy and community engagement.
Vision: A world where all people have equitable access to innovative vaccines and therapeutics.
Mission: Translate scientific discoveries into affordable, globally accessible public health solutions.
Staff in 7 countries:
- India
- Kenya
- Netherlands
- South Africa
- Uganda
- UK
- US
3 laboratories:
- Jersey City, New Jersey
- Faridabad, India
- La Jolla, California
Collaborations with GHH-partners
Aidsfonds: Part of IAVI’s Europe Hub, partner in advocacy & policy collaboration.
Overview of characteristics
Active in countries:
- Multiple countries in Africa: clinical trials, epidemiological studies & disease burden research, strengthening local capacity, partnerships for access, policy
- India/Asia: Clinical trials and immunology research, lab science, collaborations with Indian institutions.
- Europe: advocacy, policy, fundraising, partnerships. Early phase trials, European Projects (LEAP4WA, UPTAKE), collaborations with EU institutions.
- United States: vaccine design & development, antibody research center, data/trial coordination
Community of Practice (CoP):
CoP2: Pandemic Preparedness
Themes and subthemes within CoP:
- Vaccine & antibody R&D: make them affordable, globally accessible
- Clinical research & trial networks: addressing ‘vaccines & antibodies” in broader EID (emerging infectious diseases) space, including COVID19
- Access, policy & advocacy: part of IAVI’s full-circle approach
- Capacity strengthening, local systems & infrastructure
- Emerging infectious diseases, pandemic preparedness: not primarily a surveillance organization, but labs can support detection & monitoring during outbreaks,
- Cross-cutting: equity, inclusion, community engagement, ethics: ?
Organization type:
NGO
Available resources:
- Knowledge & expertise: full circle know-how in vaccines, antibodies, clinical trials, immunology: IAVI report)
- Networks & collaborations: broad network of R&D, donor, governmental, academic and regional bodies (Europe Hub, EU PDP Coalition)
- Advocacy & influence / policy: advocacy & community engagement arm, participation UN, WHA, G20 health development partnerships
- Financial / resource capacity: Europe hub works on resource mobilization, donor base including European governments, financial transparency supports credibility
- Coordination & project management: experience in leading multi-partner consortia, complex programs (CoVICIS consortium, LEAP4WA, UPTAKE)
- Capacity strengthening: local research institutions, labs, trial capabilities (LEAP4WA, partnerships with Pfizer Global Health Fellows)
- Implementation & field experience: CRC’s in Africa, Europe Hub conducts early phase clinical trials across Europe.
- Communications, publications: IAVI Report, press releases